Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) Stock Competitors & Peer Comparison
See (SYRE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYRE | $47.52 | +4.03% | 2.9B | -24.00 | -$1.98 | N/A |
| VRTX | $453.74 | -0.27% | 115.2B | 29.66 | $15.30 | N/A |
| REGN | $756.73 | +0.97% | 78.6B | 18.26 | $41.45 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ALNY | $328.16 | -0.16% | 43.5B | 140.24 | $2.34 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $692.83 | -0.61% | 42.9B | 35.64 | $19.44 | N/A |
| INSM | $147.60 | -0.48% | 31.8B | -22.99 | -$6.42 | N/A |
| UTHR | $532.53 | -1.67% | 23.3B | 19.13 | $27.84 | N/A |
| BNTX | $87.46 | -1.48% | 22B | -16.05 | -$5.45 | N/A |
Stock Comparison
SYRE vs VRTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, VRTX has a market cap of 115.2B. Regarding current trading prices, SYRE is priced at $47.52, while VRTX trades at $453.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas VRTX's P/E ratio is 29.66. In terms of profitability, SYRE's ROE is -0.29%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SYRE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check VRTX's competition here
SYRE vs REGN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, SYRE is priced at $47.52, while REGN trades at $756.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas REGN's P/E ratio is 18.26. In terms of profitability, SYRE's ROE is -0.29%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SYRE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check REGN's competition here
SYRE vs VRNA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SYRE is priced at $47.52, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SYRE's ROE is -0.29%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, SYRE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check VRNA's competition here
SYRE vs ALNY Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ALNY has a market cap of 43.5B. Regarding current trading prices, SYRE is priced at $47.52, while ALNY trades at $328.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ALNY's P/E ratio is 140.24. In terms of profitability, SYRE's ROE is -0.29%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, SYRE is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ALNY's competition here
SYRE vs SGEN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SYRE is priced at $47.52, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SYRE's ROE is -0.29%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SYRE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check SGEN's competition here
SYRE vs ARGX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ARGX has a market cap of 42.9B. Regarding current trading prices, SYRE is priced at $47.52, while ARGX trades at $692.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ARGX's P/E ratio is 35.64. In terms of profitability, SYRE's ROE is -0.29%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, SYRE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ARGX's competition here
SYRE vs INSM Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, INSM has a market cap of 31.8B. Regarding current trading prices, SYRE is priced at $47.52, while INSM trades at $147.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas INSM's P/E ratio is -22.99. In terms of profitability, SYRE's ROE is -0.29%, compared to INSM's ROE of -1.68%. Regarding short-term risk, SYRE is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check INSM's competition here
SYRE vs UTHR Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, SYRE is priced at $47.52, while UTHR trades at $532.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas UTHR's P/E ratio is 19.13. In terms of profitability, SYRE's ROE is -0.29%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SYRE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check UTHR's competition here
SYRE vs BNTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, BNTX has a market cap of 22B. Regarding current trading prices, SYRE is priced at $47.52, while BNTX trades at $87.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas BNTX's P/E ratio is -16.05. In terms of profitability, SYRE's ROE is -0.29%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, SYRE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check BNTX's competition here
SYRE vs MRNA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MRNA has a market cap of 21.2B. Regarding current trading prices, SYRE is priced at $47.52, while MRNA trades at $53.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MRNA's P/E ratio is -7.38. In terms of profitability, SYRE's ROE is -0.29%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SYRE is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check MRNA's competition here
SYRE vs BGNE Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SYRE is priced at $47.52, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SYRE's ROE is -0.29%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, SYRE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check BGNE's competition here
SYRE vs RPRX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, RPRX has a market cap of 20.1B. Regarding current trading prices, SYRE is priced at $47.52, while RPRX trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas RPRX's P/E ratio is 26.37. In terms of profitability, SYRE's ROE is -0.29%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SYRE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check RPRX's competition here
SYRE vs ROIV Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ROIV has a market cap of 19.6B. Regarding current trading prices, SYRE is priced at $47.52, while ROIV trades at $27.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ROIV's P/E ratio is -22.98. In terms of profitability, SYRE's ROE is -0.29%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, SYRE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ROIV's competition here
SYRE vs DNA-WT Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SYRE is priced at $47.52, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SYRE's ROE is -0.29%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, SYRE is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check DNA-WT's competition here
SYRE vs RVMD Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, RVMD has a market cap of 18.5B. Regarding current trading prices, SYRE is priced at $47.52, while RVMD trades at $93.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas RVMD's P/E ratio is -15.67. In terms of profitability, SYRE's ROE is -0.29%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, SYRE is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check RVMD's competition here
SYRE vs INCY Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, INCY has a market cap of 18.4B. Regarding current trading prices, SYRE is priced at $47.52, while INCY trades at $92.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas INCY's P/E ratio is 14.39. In terms of profitability, SYRE's ROE is -0.29%, compared to INCY's ROE of +0.29%. Regarding short-term risk, SYRE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check INCY's competition here
SYRE vs GMAB Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, GMAB has a market cap of 16.1B. Regarding current trading prices, SYRE is priced at $47.52, while GMAB trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas GMAB's P/E ratio is 16.90. In terms of profitability, SYRE's ROE is -0.29%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, SYRE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check GMAB's competition here
SYRE vs BBIO Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, BBIO has a market cap of 14.1B. Regarding current trading prices, SYRE is priced at $47.52, while BBIO trades at $72.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas BBIO's P/E ratio is -19.20. In terms of profitability, SYRE's ROE is -0.29%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, SYRE is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check BBIO's competition here
SYRE vs ASND Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, SYRE is priced at $47.52, while ASND trades at $220.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ASND's P/E ratio is -51.16. In terms of profitability, SYRE's ROE is -0.29%, compared to ASND's ROE of +1.28%. Regarding short-term risk, SYRE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check ASND's competition here
SYRE vs SMMT Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, SMMT has a market cap of 12.8B. Regarding current trading prices, SYRE is priced at $47.52, while SMMT trades at $17.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas SMMT's P/E ratio is -11.99. In terms of profitability, SYRE's ROE is -0.29%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, SYRE is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check SMMT's competition here
SYRE vs KRTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SYRE is priced at $47.52, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SYRE's ROE is -0.29%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SYRE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check KRTX's competition here
SYRE vs IONS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, IONS has a market cap of 12.3B. Regarding current trading prices, SYRE is priced at $47.52, while IONS trades at $74.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas IONS's P/E ratio is -31.19. In terms of profitability, SYRE's ROE is -0.29%, compared to IONS's ROE of -0.69%. Regarding short-term risk, SYRE is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check IONS's competition here
SYRE vs MDGL Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, SYRE is priced at $47.52, while MDGL trades at $518.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MDGL's P/E ratio is -40.34. In terms of profitability, SYRE's ROE is -0.29%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, SYRE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check MDGL's competition here
SYRE vs JAZZ Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, SYRE is priced at $47.52, while JAZZ trades at $189.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas JAZZ's P/E ratio is -32.33. In terms of profitability, SYRE's ROE is -0.29%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, SYRE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check JAZZ's competition here
SYRE vs EXEL Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, EXEL has a market cap of 11.4B. Regarding current trading prices, SYRE is priced at $47.52, while EXEL trades at $42.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas EXEL's P/E ratio is 15.24. In terms of profitability, SYRE's ROE is -0.29%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, SYRE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check EXEL's competition here
SYRE vs RNAM Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SYRE is priced at $47.52, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SYRE's ROE is -0.29%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SYRE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check RNAM's competition here
SYRE vs BMRN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, SYRE is priced at $47.52, while BMRN trades at $55.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas BMRN's P/E ratio is 30.86. In terms of profitability, SYRE's ROE is -0.29%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, SYRE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check BMRN's competition here
SYRE vs RXDX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SYRE is priced at $47.52, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SYRE's ROE is -0.29%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SYRE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check RXDX's competition here
SYRE vs IMGN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SYRE is priced at $47.52, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SYRE's ROE is -0.29%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SYRE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check IMGN's competition here
SYRE vs ARWR Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, SYRE is priced at $47.52, while ARWR trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ARWR's P/E ratio is 38.01. In terms of profitability, SYRE's ROE is -0.29%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, SYRE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check ARWR's competition here
SYRE vs AXSM Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, AXSM has a market cap of 8.4B. Regarding current trading prices, SYRE is priced at $47.52, while AXSM trades at $164.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas AXSM's P/E ratio is -44.78. In terms of profitability, SYRE's ROE is -0.29%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, SYRE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check AXSM's competition here
SYRE vs BPMC Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SYRE is priced at $47.52, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SYRE's ROE is -0.29%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, SYRE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check BPMC's competition here
SYRE vs TECH Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, SYRE is priced at $47.52, while TECH trades at $52.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas TECH's P/E ratio is 99.43. In terms of profitability, SYRE's ROE is -0.29%, compared to TECH's ROE of +0.04%. Regarding short-term risk, SYRE is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check TECH's competition here
SYRE vs CERE Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SYRE is priced at $47.52, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CERE's P/E ratio is -16.47. In terms of profitability, SYRE's ROE is -0.29%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SYRE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CERE's competition here
SYRE vs PCVX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, SYRE is priced at $47.52, while PCVX trades at $54.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas PCVX's P/E ratio is -9.72. In terms of profitability, SYRE's ROE is -0.29%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, SYRE is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check PCVX's competition here
SYRE vs CYTK Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, SYRE is priced at $47.52, while CYTK trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CYTK's P/E ratio is -9.71. In terms of profitability, SYRE's ROE is -0.29%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, SYRE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CYTK's competition here
SYRE vs IBRX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, SYRE is priced at $47.52, while IBRX trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas IBRX's P/E ratio is -19.42. In terms of profitability, SYRE's ROE is -0.29%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, SYRE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check IBRX's competition here
SYRE vs HALO Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, SYRE is priced at $47.52, while HALO trades at $63.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas HALO's P/E ratio is 24.72. In terms of profitability, SYRE's ROE is -0.29%, compared to HALO's ROE of +0.93%. Regarding short-term risk, SYRE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check HALO's competition here
SYRE vs MTSR Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SYRE is priced at $47.52, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SYRE's ROE is -0.29%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, SYRE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check MTSR's competition here
SYRE vs KRYS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, KRYS has a market cap of 7.3B. Regarding current trading prices, SYRE is priced at $47.52, while KRYS trades at $251.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas KRYS's P/E ratio is 36.81. In terms of profitability, SYRE's ROE is -0.29%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SYRE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check KRYS's competition here
SYRE vs ABVX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ABVX has a market cap of 7.2B. Regarding current trading prices, SYRE is priced at $47.52, while ABVX trades at $109.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ABVX's P/E ratio is -19.53. In terms of profitability, SYRE's ROE is -0.29%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, SYRE is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ABVX's competition here
SYRE vs NUVL Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, NUVL has a market cap of 7.2B. Regarding current trading prices, SYRE is priced at $47.52, while NUVL trades at $98.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas NUVL's P/E ratio is -16.76. In terms of profitability, SYRE's ROE is -0.29%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, SYRE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check NUVL's competition here
SYRE vs MRUS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SYRE is priced at $47.52, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SYRE's ROE is -0.29%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, SYRE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check MRUS's competition here
SYRE vs ACLX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SYRE is priced at $47.52, while ACLX trades at $114.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ACLX's P/E ratio is -28.17. In terms of profitability, SYRE's ROE is -0.29%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SYRE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ACLX's competition here
SYRE vs RETA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SYRE is priced at $47.52, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas RETA's P/E ratio is -66.29. In terms of profitability, SYRE's ROE is -0.29%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SYRE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check RETA's competition here
SYRE vs KYMR Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, SYRE is priced at $47.52, while KYMR trades at $80.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas KYMR's P/E ratio is -21.73. In terms of profitability, SYRE's ROE is -0.29%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, SYRE is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check KYMR's competition here
SYRE vs PTGX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, PTGX has a market cap of 6.5B. Regarding current trading prices, SYRE is priced at $47.52, while PTGX trades at $102.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas PTGX's P/E ratio is -49.84. In terms of profitability, SYRE's ROE is -0.29%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, SYRE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check PTGX's competition here
SYRE vs PRAX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, PRAX has a market cap of 6.4B. Regarding current trading prices, SYRE is priced at $47.52, while PRAX trades at $302.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas PRAX's P/E ratio is -22.47. In terms of profitability, SYRE's ROE is -0.29%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, SYRE is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check PRAX's competition here
SYRE vs COGT Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, COGT has a market cap of 6B. Regarding current trading prices, SYRE is priced at $47.52, while COGT trades at $36.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas COGT's P/E ratio is -17.07. In terms of profitability, SYRE's ROE is -0.29%, compared to COGT's ROE of -1.00%. Regarding short-term risk, SYRE is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check COGT's competition here
SYRE vs BLTE Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, SYRE is priced at $47.52, while BLTE trades at $149.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas BLTE's P/E ratio is -64.52. In terms of profitability, SYRE's ROE is -0.29%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, SYRE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check BLTE's competition here
SYRE vs CGON Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, SYRE is priced at $47.52, while CGON trades at $66.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CGON's P/E ratio is -32.53. In terms of profitability, SYRE's ROE is -0.29%, compared to CGON's ROE of -0.23%. Regarding short-term risk, SYRE is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CGON's competition here
SYRE vs CDTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SYRE is priced at $47.52, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SYRE's ROE is -0.29%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, SYRE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CDTX's competition here
SYRE vs RYTM Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, SYRE is priced at $47.52, while RYTM trades at $81.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas RYTM's P/E ratio is -26.33. In terms of profitability, SYRE's ROE is -0.29%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, SYRE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check RYTM's competition here
SYRE vs PTCT Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, SYRE is priced at $47.52, while PTCT trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas PTCT's P/E ratio is 7.81. In terms of profitability, SYRE's ROE is -0.29%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, SYRE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check PTCT's competition here
SYRE vs ABCM Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SYRE is priced at $47.52, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SYRE's ROE is -0.29%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SYRE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ABCM's competition here
SYRE vs ISEE Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SYRE is priced at $47.52, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SYRE's ROE is -0.29%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SYRE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ISEE's competition here
SYRE vs FBIOX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, SYRE is priced at $47.52, while FBIOX trades at $24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas FBIOX's P/E ratio is N/A. In terms of profitability, SYRE's ROE is -0.29%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, SYRE is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check FBIOX's competition here
SYRE vs CELC Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, SYRE is priced at $47.52, while CELC trades at $114.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CELC's P/E ratio is -31.20. In terms of profitability, SYRE's ROE is -0.29%, compared to CELC's ROE of -2.03%. Regarding short-term risk, SYRE is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check CELC's competition here
SYRE vs CAI Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, SYRE is priced at $47.52, while CAI trades at $18.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CAI's P/E ratio is -5.69. In terms of profitability, SYRE's ROE is -0.29%, compared to CAI's ROE of +0.25%. Regarding short-term risk, SYRE is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CAI's competition here
SYRE vs IMVT Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, IMVT has a market cap of 5.2B. Regarding current trading prices, SYRE is priced at $47.52, while IMVT trades at $25.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas IMVT's P/E ratio is -9.16. In terms of profitability, SYRE's ROE is -0.29%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, SYRE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check IMVT's competition here
SYRE vs TGTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, TGTX has a market cap of 5.1B. Regarding current trading prices, SYRE is priced at $47.52, while TGTX trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas TGTX's P/E ratio is 11.55. In terms of profitability, SYRE's ROE is -0.29%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, SYRE is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check TGTX's competition here
SYRE vs SRRK Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, SYRE is priced at $47.52, while SRRK trades at $44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas SRRK's P/E ratio is -13.44. In terms of profitability, SYRE's ROE is -0.29%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, SYRE is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check SRRK's competition here
SYRE vs ALKS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, SYRE is priced at $47.52, while ALKS trades at $29.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ALKS's P/E ratio is 20.93. In terms of profitability, SYRE's ROE is -0.29%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, SYRE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ALKS's competition here
SYRE vs TERN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SYRE is priced at $47.52, while TERN trades at $53.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas TERN's P/E ratio is -52.13. In terms of profitability, SYRE's ROE is -0.29%, compared to TERN's ROE of -0.30%. Regarding short-term risk, SYRE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check TERN's competition here
SYRE vs ERAS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, SYRE is priced at $47.52, while ERAS trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ERAS's P/E ratio is -34.45. In terms of profitability, SYRE's ROE is -0.29%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, SYRE is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check ERAS's competition here
SYRE vs XENE Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, SYRE is priced at $47.52, while XENE trades at $55.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas XENE's P/E ratio is -12.74. In terms of profitability, SYRE's ROE is -0.29%, compared to XENE's ROE of -0.56%. Regarding short-term risk, SYRE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check XENE's competition here
SYRE vs CRSP Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, SYRE is priced at $47.52, while CRSP trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CRSP's P/E ratio is -7.35. In terms of profitability, SYRE's ROE is -0.29%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, SYRE is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CRSP's competition here
SYRE vs FOLD Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SYRE is priced at $47.52, while FOLD trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas FOLD's P/E ratio is -160.33. In terms of profitability, SYRE's ROE is -0.29%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SYRE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check FOLD's competition here
SYRE vs AKRO Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SYRE is priced at $47.52, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SYRE's ROE is -0.29%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, SYRE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check AKRO's competition here
SYRE vs MIRM Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MIRM has a market cap of 4.5B. Regarding current trading prices, SYRE is priced at $47.52, while MIRM trades at $88.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MIRM's P/E ratio is -189.11. In terms of profitability, SYRE's ROE is -0.29%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, SYRE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check MIRM's competition here
SYRE vs ALPN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SYRE is priced at $47.52, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SYRE's ROE is -0.29%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SYRE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ALPN's competition here
SYRE vs APGE Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, APGE has a market cap of 4.3B. Regarding current trading prices, SYRE is priced at $47.52, while APGE trades at $78.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas APGE's P/E ratio is -20.15. In terms of profitability, SYRE's ROE is -0.29%, compared to APGE's ROE of -0.37%. Regarding short-term risk, SYRE is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check APGE's competition here
SYRE vs OPT Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SYRE is priced at $47.52, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas OPT's P/E ratio is -1.52. In terms of profitability, SYRE's ROE is -0.29%, compared to OPT's ROE of +0.88%. Regarding short-term risk, SYRE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check OPT's competition here
SYRE vs MRTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SYRE is priced at $47.52, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SYRE's ROE is -0.29%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SYRE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check MRTX's competition here
SYRE vs CORT Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CORT has a market cap of 4.1B. Regarding current trading prices, SYRE is priced at $47.52, while CORT trades at $38.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CORT's P/E ratio is 47.01. In terms of profitability, SYRE's ROE is -0.29%, compared to CORT's ROE of +0.15%. Regarding short-term risk, SYRE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CORT's competition here
SYRE vs LGND Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, SYRE is priced at $47.52, while LGND trades at $203.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas LGND's P/E ratio is 33.23. In terms of profitability, SYRE's ROE is -0.29%, compared to LGND's ROE of +0.14%. Regarding short-term risk, SYRE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check LGND's competition here
SYRE vs VKTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, SYRE is priced at $47.52, while VKTX trades at $34.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas VKTX's P/E ratio is -10.74. In terms of profitability, SYRE's ROE is -0.29%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, SYRE is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check VKTX's competition here
SYRE vs CNTA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CNTA has a market cap of 4B. Regarding current trading prices, SYRE is priced at $47.52, while CNTA trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CNTA's P/E ratio is -15.39. In terms of profitability, SYRE's ROE is -0.29%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, SYRE is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check CNTA's competition here
SYRE vs CRNX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, SYRE is priced at $47.52, while CRNX trades at $36.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CRNX's P/E ratio is -7.34. In terms of profitability, SYRE's ROE is -0.29%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, SYRE is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CRNX's competition here
SYRE vs RYZB Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SYRE is priced at $47.52, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SYRE's ROE is -0.29%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SYRE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check RYZB's competition here
SYRE vs CBAY Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SYRE is priced at $47.52, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SYRE's ROE is -0.29%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SYRE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CBAY's competition here
SYRE vs ACAD Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, SYRE is priced at $47.52, while ACAD trades at $21.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ACAD's P/E ratio is 9.34. In terms of profitability, SYRE's ROE is -0.29%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, SYRE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ACAD's competition here
SYRE vs NAMS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, SYRE is priced at $47.52, while NAMS trades at $31.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas NAMS's P/E ratio is -18.17. In terms of profitability, SYRE's ROE is -0.29%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, SYRE is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check NAMS's competition here
SYRE vs SWTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SYRE is priced at $47.52, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SYRE's ROE is -0.29%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, SYRE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check SWTX's competition here
SYRE vs KNSA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, SYRE is priced at $47.52, while KNSA trades at $46.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas KNSA's P/E ratio is 62.37. In terms of profitability, SYRE's ROE is -0.29%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, SYRE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check KNSA's competition here
SYRE vs EWTX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, EWTX has a market cap of 3.4B. Regarding current trading prices, SYRE is priced at $47.52, while EWTX trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas EWTX's P/E ratio is -19.42. In terms of profitability, SYRE's ROE is -0.29%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, SYRE is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check EWTX's competition here
SYRE vs LQDA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, LQDA has a market cap of 3.2B. Regarding current trading prices, SYRE is priced at $47.52, while LQDA trades at $36.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas LQDA's P/E ratio is -45.96. In terms of profitability, SYRE's ROE is -0.29%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, SYRE is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check LQDA's competition here
SYRE vs LEGN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, SYRE is priced at $47.52, while LEGN trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas LEGN's P/E ratio is -10.87. In terms of profitability, SYRE's ROE is -0.29%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, SYRE is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check LEGN's competition here
SYRE vs DNTH Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, SYRE is priced at $47.52, while DNTH trades at $82.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas DNTH's P/E ratio is -23.56. In terms of profitability, SYRE's ROE is -0.29%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, SYRE is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check DNTH's competition here
SYRE vs DNLI Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, SYRE is priced at $47.52, while DNLI trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas DNLI's P/E ratio is -6.65. In terms of profitability, SYRE's ROE is -0.29%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, SYRE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for SYRE.Check DNLI's competition here
SYRE vs ALMS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, SYRE is priced at $47.52, while ALMS trades at $26.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas ALMS's P/E ratio is -9.20. In terms of profitability, SYRE's ROE is -0.29%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, SYRE is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check ALMS's competition here
SYRE vs DYN Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, SYRE is priced at $47.52, while DYN trades at $18.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas DYN's P/E ratio is -5.35. In terms of profitability, SYRE's ROE is -0.29%, compared to DYN's ROE of -0.61%. Regarding short-term risk, SYRE is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check DYN's competition here
SYRE vs TLX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, TLX has a market cap of 3B. Regarding current trading prices, SYRE is priced at $47.52, while TLX trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas TLX's P/E ratio is -448.50. In terms of profitability, SYRE's ROE is -0.29%, compared to TLX's ROE of -0.02%. Regarding short-term risk, SYRE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check TLX's competition here
SYRE vs CPRX Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, SYRE is priced at $47.52, while CPRX trades at $24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas CPRX's P/E ratio is 14.43. In terms of profitability, SYRE's ROE is -0.29%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SYRE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check CPRX's competition here
SYRE vs VERA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, SYRE is priced at $47.52, while VERA trades at $40.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas VERA's P/E ratio is -8.64. In terms of profitability, SYRE's ROE is -0.29%, compared to VERA's ROE of -0.60%. Regarding short-term risk, SYRE is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check VERA's competition here
SYRE vs MORF Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, SYRE is priced at $47.52, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MORF's P/E ratio is -14.88. In terms of profitability, SYRE's ROE is -0.29%, compared to MORF's ROE of -0.29%. Regarding short-term risk, SYRE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check MORF's competition here
SYRE vs TARS Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, TARS has a market cap of 2.9B. Regarding current trading prices, SYRE is priced at $47.52, while TARS trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas TARS's P/E ratio is -42.26. In terms of profitability, SYRE's ROE is -0.29%, compared to TARS's ROE of -0.20%. Regarding short-term risk, SYRE is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check TARS's competition here
SYRE vs MOR Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, SYRE is priced at $47.52, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas MOR's P/E ratio is -12.64. In terms of profitability, SYRE's ROE is -0.29%, compared to MOR's ROE of -1.84%. Regarding short-term risk, SYRE is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check MOR's competition here
SYRE vs IDYA Comparison March 2026
SYRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 2.9B. In comparison, IDYA has a market cap of 2.8B. Regarding current trading prices, SYRE is priced at $47.52, while IDYA trades at $32.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -24.00, whereas IDYA's P/E ratio is -25.07. In terms of profitability, SYRE's ROE is -0.29%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, SYRE is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for SYRE.Check IDYA's competition here